Summit Therapeutics SMMT
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Summit Therapeutics (SMMT) Business Model and Operations Summary
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Key Insights
Summit Therapeutics (SMMT) Core Market Data and Business Metrics
Latest Closing Price
$26.74Market Cap
$15.14 BillionAverage Daily Volume
4,750,193 Shares52-Week Range
$6.78-$36.91Price-Earnings Ratio
-76.40Total Outstanding Shares
742.67 Million SharesCEO
Mr. Robert W. DugganTotal Employees
159Current Dividend
No dividendIPO Date
March 5, 2015SIC Description
Pharmaceutical PreparationsHeadquarters
601 Brickell Key Drive, Miami, FL, 33131